KathleenJYostMD

Oncology • Grand Rapids, MI

Physician

Join to view full profile

Dr. Yost is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Yost's full profile

Already have an account?

Office
25 Michigan St Suite 3100
MC 012
Grand Rapids, MI 49503
Phone+1 616-391-1230
Is this information wrong?

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989
Spectrum Health/Michigan State UniversityResidency, Internal Medicine, 1983 - 1987
University of Michigan Medical SchoolClass of 1983

Certifications & Licensure

MI State Medical License 1989 - 2026
TN State Medical License 1988 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012-2013

Clinical Trials

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Collection and Storage of Tissue and Blood Samples From Patients With Cancer Start of enrollment: 2015 May 19
Recruiting
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome Start of enrollment: 2015 Dec 23
Completed
Not Applicable
Understanding and Predicting Breast Cancer Events After Treatment Start of enrollment: 2017 Jul 21
Active, not recruiting
Not Applicable
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil Start of enrollment: 2017 May 30
Completed
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer Start of enrollment: 2017 May 26
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
Active, not recruiting
Phase 3
Use of a Pre-Surgical Toolkit in Improving Surgical Care and Outcomes in Older Participants With Cancer Start of enrollment: 2019 Jul 24
Active, not recruiting
Not Applicable
Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Start of enrollment: 2019 Aug 02
Active, not recruiting
Not Applicable
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer Start of enrollment: 2019 May 14
Active, not recruiting
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer Start of enrollment: 2019 May 17
Active, not recruiting
Phase 2
Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer Start of enrollment: 2019 Jul 19
Active, not recruiting
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer Start of enrollment: 2019 Sep 23
Recruiting
Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker Start of enrollment: 2020 Jul 20
Active, not recruiting
Phase 2
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy Start of enrollment: 2020 Sep 10
Completed
Not Applicable
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma Start of enrollment: 2019 Dec 17
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

117 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
6 citations
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer WithMutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Kelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, Pam K Mangat, Reza Nazemzadeh, Kathleen J Yost, Herbert L Duvivier, Eugene R Ahn, Timothy L Cannon, Olatunji B ...> ;JCO Precision Oncology. 2022 Nov 1
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
Marsha Reyngold, Kathryn A Winter, William F Regine, Ross A Abrams, Howard Safran, John P Hoffman, Rex B Mowat, John P Hayes, Ivan L Kessel, Thomas DiPetrillo, Samir N...> ;The Oncologist. 2020 Mar 1
46 citations
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Tareq Al Baghdadi, Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Eugene R Ahn, Vaibhav Sahai, Ricardo H. Alvarez, Edward S. Kim, Kathleen J. Yost, Andrew L. Ry...> ;JCO Precision Oncology. 2019 Aug 14
26 citations
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II).
John D. Hainsworth, Kevin P. Becker, Tarek Mekhail, Sajeel A. Chowdhary, Janice Faulkner Eakle, David Wright, Robert M. Langdon, Kathleen Yost, Gilbert Darin Anthony P...> ;Journal of Neuro-Oncology. 2019 Aug 7
77 citations
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K. Mangat, Susan Halabi, Suanna S. Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A. Janeway, Philip J. Stella, Emile E. Voest, Kathleen J. Yost, Jane P...> ;JCO Precision Oncology. 2018 Jul 11
5 citations
Effect of single agent high-dose methotrexate-related acute kidney injury on length of hospitalization and relative dose intensity in adult patients with central nervo...
Jennifer S Steward, Heather Bullard, Timothy J O'Rourke, Alan D Campbell, Brett T Brinker, Kathleen J Yost, Amy C Vanderwoude, William L Scott, Polly E Kintzel> ;Journal of Oncology Pharmacy Practice. 2017 Oct 1
12 citations
Reduced time for urinary alkalinization before high-dose methotrexate with preadmission oral bicarbonate.
Polly E Kintzel, Alan D. Campbell, Kathleen J. Yost, Brett T Brinker, Nicole V Arradaza, Daniel Frobish, Alison M Wehr, Timothy J. O'Rourke> ;Journal of Oncology Pharmacy Practice. 2012 Jun 1
10 citations
Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
Marianne Melnik, Craig P. Webb, Patrick J. Richardson, Charles R. Luttenton, Alan D. Campbell, Thomas Monroe, Timothy J. O'Rourke, Kathleen J. Yost, Connie M. Szczepan...> ;Molecular Cancer Therapeutics. 2010 Aug 1
56 citations
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
John D. Hainsworth, David R. Spigel, Jeffrey A. Sosman, Howard A. Burris, C. Farley, Heather Cucullu, Kathleen Yost, Lowell L. Hart, Linda Sylvester, David M. Waterhou...> ;Clinical Genitourinary Cancer. 2007 Dec 1
7 citations
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
James H. Doroshow, Sheryl McCoy, Brian F. Issell, Taral Patel, Patrick W. Cobb, Kathleen J. Yost, James L. Abbruzzese> ;Investigational New Drugs. 2006 Jul 10
9 citations
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Stephen K. Williamson, Sheryl McCoy, David R. Gandara, Shaker R. Dakhil, Kathleen J. Yost, Jorge C. Paradelo, James N. Atkins, Charles D. Blanke, James L. Abbruzzese> ;American Journal of Clinical Oncology. 2006 Apr 1
5 citations
Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II tri...
John D. Hainsworth, A. A. Meluch, David R. Spigel, Kathleen Yost, Christina Meng, F. Anthony Greco> ;Clinical Genitourinary Cancer. 2006 Mar 1
23 citations
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Netwo...
John D. Hainsworth, David R. Spigel, Eric L. Raefsky, Michel E. Kuzur, Kathleen Yost, Kommor M, Sharlene Litchy, F. Anthony Greco> ;Cancer. 2005 Nov 1
Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial.
Hainsworth JD, Sosman JA, Spigel DR, Patton JF, Thompson DS, Sutton V, Hart LL, Yost K, Greco FA> ;J. Clin. Oncol.. 2005-06-01
Bevacizumab and erlotinib in the treatment of patients with metastatic renal carcinoma (RCC): Update of a phase II multicenter trial.
Spigel DR, Hainsworth JD, Sosman JA, Raefsky EL, Meluch AA, Edwards D, Horowitz P, Thomas K, Yost K, Stagg MP, Greco FA> ;J. Clin. Oncol.. 2005-06-01
Rituximab with short duration chemotherapy followed by 90Y ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: Update of a Minnie Pearl...
Shipley DL, Greco FA, Spigel DR, Edwards D, Mayfield M, Yost K, Allerton JP, Hainsworth JD> ;J. Clin. Oncol.. 2005-06-01
40 citations
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
John D. Hainsworth, A. A. Meluch, Sharlene Litchy, Frederick M. Schnell, James D. Bearden, Kathleen Yost, F. Anthony Greco> ;Cancer. 2005 Jun 1
Interferon alpha-2b and thalidomide in previously treated patients with disseminated malignant melanoma: SWOG 0026.
Hutchins L, Moon J, Clark J, Thompson J, Yost K, Sondak V> ;J. Clin. Oncol.. 2004-07-15
93 citations
Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Ca...
A. A. Meluch, F. Anthony Greco, J. R. Gray, M. Thomas, Valerie M. Sutton, J. Lucian Davis, L A Kalman, Don W. Shaffer, Kathleen Yost, David Rinaldi, John D. Hainsworth> ;Cancer Journal. 2003 Jul 1
38 citations
Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced ...
John D. Hainsworth, A. A. Meluch, Suzanne Mcclurkan, J. R. Gray, Steven L. Stroup, Howard A. Burris, Denise A. Yardley, James E. Bradof, Kathleen Yost, James K. Ellis,...> ;Cancer Journal. 2002 Jul 1
Join now to see all

Grant Support

Grand Rapids Clinical Oncology ProgramNational Cancer Institute2001–2004

Hospital Affiliations

Corewell Health - Butterworth HospitalGrand Rapids, Michigan
Corewell Health Reed City HospitalReed City, Michigan
Corewell Health Pennock HospitalHastings, Michigan
Corewell Health Ludington HospitalLudington, Michigan

KathleenJYostMD

Dr. Yost is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.